BR9914792A - Uso de agentes antifúngicos para tratamento deescleroses - Google Patents

Uso de agentes antifúngicos para tratamento deescleroses

Info

Publication number
BR9914792A
BR9914792A BR9914792-0A BR9914792A BR9914792A BR 9914792 A BR9914792 A BR 9914792A BR 9914792 A BR9914792 A BR 9914792A BR 9914792 A BR9914792 A BR 9914792A
Authority
BR
Brazil
Prior art keywords
antifungal agents
sclerosis
fungi
derived
genus
Prior art date
Application number
BR9914792-0A
Other languages
English (en)
Inventor
Roumen Antonov
Original Assignee
Candida Medical B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Candida Medical B V filed Critical Candida Medical B V
Publication of BR9914792A publication Critical patent/BR9914792A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Patente de Invenção para "USO DE AGENTES ANTIFúNGICOSPARA TRATAMENTO DE ESCLEROSES". A invenção se refereao uso de agentes antifúngicos ativos sobre os fungos do gêneroCândida, e como no caso podendo ser do gênero Rodhotorula,para preparação medicinais para prevenção ou tratamento dasescleroses dos tecidos, e outras patologias derivadas, noshumanos ou nos animal, relacionados à presença no organismohumano ou animal dos fungos derivados a partir daquelesmencionados acima.
BR9914792-0A 1998-10-27 1999-10-27 Uso de agentes antifúngicos para tratamento deescleroses BR9914792A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/FR1998/002302 WO2000024402A1 (fr) 1998-10-27 1998-10-27 Utilisation d'antifongiques dans le traitement des scleroses
PCT/FR1999/002617 WO2000024403A1 (fr) 1998-10-27 1999-10-27 Utilisation d'antifongiques dans le traitement des scleroses

Publications (1)

Publication Number Publication Date
BR9914792A true BR9914792A (pt) 2001-11-27

Family

ID=9523370

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9914792-0A BR9914792A (pt) 1998-10-27 1999-10-27 Uso de agentes antifúngicos para tratamento deescleroses

Country Status (8)

Country Link
EP (1) EP1124560A1 (pt)
JP (1) JP2002528064A (pt)
CN (1) CN1328466A (pt)
AU (2) AU1036999A (pt)
BR (1) BR9914792A (pt)
CA (1) CA2348160A1 (pt)
IL (1) IL142641A0 (pt)
WO (2) WO2000024402A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915625D0 (en) * 1999-07-02 1999-09-01 Cortendo Ab Method
CN110269939A (zh) * 2019-03-12 2019-09-24 武汉愔紫生物科技有限公司 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法
CN110343650B (zh) * 2019-05-28 2020-12-29 浙江工业大学 一种产两性霉素b的重组结节链霉菌及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL169682C (nl) * 1969-07-07 1982-08-16 Schmid Lab Werkwijze ter bereiding van een hypocholesterolemisch preparaat.
US4289757A (en) * 1978-02-28 1981-09-15 The Upjohn Company Method for treating inflammation
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
GB2290707A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of Amphotericin B
GB2290709A (en) * 1994-06-28 1996-01-10 Georgi Stankov Pharmaceutical uses of nystatin

Also Published As

Publication number Publication date
CA2348160A1 (fr) 2000-05-04
WO2000024403A1 (fr) 2000-05-04
EP1124560A1 (fr) 2001-08-22
AU1036999A (en) 2000-05-15
JP2002528064A (ja) 2002-09-03
IL142641A0 (en) 2002-03-10
CN1328466A (zh) 2001-12-26
AU6347199A (en) 2000-05-15
WO2000024402A1 (fr) 2000-05-04

Similar Documents

Publication Publication Date Title
BR0311313A (pt) Derivados de diaril uréia úteis para o tratamento de doenças dependentes de proteìna cinase
BR0109446A (pt) Medicamento para a aplicação intracorpórea, uso de um xanteno halogenado, composição farmacêutica, e, método de tratamento
FR2843125B1 (fr) Principes actifs stimulant les beta-defensives humaines de type 2 et/ou de type 3, et compositions cosmetiques ou pharmaceutiques comprenant de tels principes actifs
ATE386533T1 (de) Kosmetische zubereitungen enthaltend polyhexamethhylenbiguanid-hydrochlorid und distearyldimethylammoniumchlorid
MX9100042A (es) Reduccion o prevencion de irritacion de la piel por drogas
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
TR200101649T2 (tr) Piperazin türevleri.
PT1001792E (pt) Utilizacao de compostos de sais e de complexos de vanadio aceites fisiologicamente
CA2216569A1 (fr) Utilisation de derives d'oxazolidinone comme agents anti-penetrants dans une composition cosmetique et/ou dermatologique
BR0200921A (pt) Uso de produtos de legume para o tratamento de agressões externas
BR9814214A (pt) Composição com ácido azeláico
BR9916432A (pt) Compostos de triazinona para o tratamento de doenças devido ao sarcosystis, neospora e ao toxoplasma
DE60018409D1 (de) Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
HK1037980A1 (en) Use of selegiline or desmethylselegiline for the manufacture of a medicament for treating wounds, burns or photodamage.
BR9913337A (pt) Derivados tan-1057
BR9914792A (pt) Uso de agentes antifúngicos para tratamento deescleroses
ATE185274T1 (de) Therapeutisches mittel gegen drohenden abortus
PT983300E (pt) Sais peptidicos de bpc com actividade organo-protectora, processo para a sua preparacao e sua utilizacao em terapia
CY1106702T1 (el) Χρηση ενος συνδυασμου μιας πουρινης και ενος παραγοντα δοτη μονοξειδιου του αζωτου για την προληψη ή την αγωγη γενετησιων δυσλειτουργιων
BR0104586A (pt) Método para tratamento de neurodegeneração
ATE238050T1 (de) 4-cyano-4-deformylsordarizin-derivate
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
ATE241979T1 (de) 4-cyano-4-deformylsordarinderivate
FR2747572B1 (fr) Nouvelles compositions cosmetiques, dermopharmaceutiques ou veterinaires pour le traitement aseptisant de la peau humaine ou animale
FR2818147B1 (fr) Nouvelle application therapeutique d'un derive de la thienyclyclohexylamine

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]